PMID- 35593668
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220908
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 73
IP  - 4
DP  - 2022
TI  - Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with 
      potential metabolic activity in the treatment of type 2 diabetes.
PG  - 745-755
LID - 10.5603/EP.a2022.0029 [doi]
AB  - The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent 
      insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial 
      insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 
      receptor agonist in the form of a synthetic linear peptide; its acylation 
      technology allows it to bind to albumin, thus making it possible to dose the drug 
      once a week. This review summarizes the key characteristics and pharmacokinetics 
      of tirzepatide. The authors present the results of a phase 1, 2, and 3 clinical 
      trial on the effects of tirzepatide on glycaemic and lipid control and the 
      beneficial effects on body weight in a dose-dependent manner in patients with 
      type 2 diabetes mellitus (T2DM). Tirzepatide has the ability to reduce glycaemic 
      levels, improve insulin sensitivity, reduce body weight, and improve lipid 
      metabolism, which is critically important in T2DM. Tirzepatide administered by 
      weekly subcutaneous injections appears to be a promising drug for the treatment 
      of T2DM as well as cardiometabolic disorders. The mechanism of action and safety 
      profile of tirzepatide potentially fills important gaps in the current treatment 
      of T2DM.
FAU - Nowak, Mariusz
AU  - Nowak M
AUID- ORCID: 0000-0003-1754-9959
AD  - Pathophysiology Division, Department of Pathophysiology and Endocrinology, 
      Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 
      Poland. nowak-mar@wp.pl.
FAU - Nowak, Wojciech
AU  - Nowak W
AD  - Science Students' Association, Pathophysiology Division, Department of 
      Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical 
      University of Silesia in Katowice, Poland., Poland.
FAU - Grzeszczak, Wladyslaw
AU  - Grzeszczak W
AUID- ORCID: 0000-0003-1947-3783
AD  - Department of Internal Medicine, Diabetology and Nephrology, FMS in Zabrze, SUM 
      41-800 Zabrze , Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220520
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - OYN3CCI6QE (tirzepatide)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - Gastric Inhibitory Polypeptide
MH  - Glucagon-Like Peptide-1 Receptor/agonists/therapeutic use
MH  - Humans
MH  - *Hypoglycemic Agents/pharmacology/therapeutic use
OTO - NOTNLM
OT  - glucagon-like peptide-1 (GLP-1)
OT  - glucose-dependent insulinotropic polypeptide (GIP)
OT  - tirzepatide
OT  - type 2 diabetes
EDAT- 2022/05/21 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/05/20 09:32
PHST- 2022/01/09 00:00 [received]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/01/17 00:00 [revised]
PHST- 2022/05/21 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2022/05/20 09:32 [entrez]
AID - VM/OJS/J/87859 [pii]
AID - 10.5603/EP.a2022.0029 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2022;73(4):745-755. doi: 10.5603/EP.a2022.0029. Epub 2022 May 20.